| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3901077 | Urology | 2011 | 5 Pages |
Abstract
The complete loss of SMARCB1/INI1 immunoexpression was found in 15% of CDC. No differences were found between the SMARCB1/INI1 positive and negative cases regarding the clinicopathologic and outcome features. Our results suggest that some CDC cases might be associated with genetic alterations involving the SMARCB1/INI1 gene. In addition, SMARCB1/INI1 immunoexpression seems to be of limited value in the differential diagnosis of CDC versus renal medullary carcinoma, although these results require additional validation.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Hillary Elwood, Alcides Chaux, Luciana Schultz, Peter B. Illei, Dilek E. Baydar, Athanase Billis, Rajni Sharma, Pedram Argani, Jonathan I. Epstein, George J. Netto,